Product Benefits

The Emjard-M 12.5/500mg Tablet, a fixed-dose combination of Empagliflozin and Metformin Hydrochloride, offers several therapeutic advantages for managing Type 2 Diabetes Mellitus:

1. Comprehensive Glycemic Control: It combines two complementary mechanisms of action to lower blood sugar (glucose) levels more effectively than either component alone.

   • Empagliflozin (an SGLT2 inhibitor) works by preventing the kidneys from reabsorbing glucose back into the bloodstream, increasing the excretion of glucose through the urine.

   • Metformin (a Biguanide) primarily works by decreasing glucose production in the liver and improving the body's sensitivity to insulin, which increases peripheral glucose uptake.

2. Reduced Risk of Cardiovascular Death: For adults with Type 2 Diabetes and established cardiovascular disease, this medicine is indicated to reduce the risk of dying from cardiovascular causes.

3. Protection Against Diabetes Complications: By consistently lowering and controlling blood glucose levels, the medication helps reduce the risk of long-term and serious complications associated with diabetes, such as:

   • Kidney damage (nephropathy)

   • Eye damage (retinopathy)

   • Nerve problems (neuropathy)

   • Loss of limbs

4. Weight Management Support: SGLT2 inhibitors like Empagliflozin often lead to modest weight loss due to the excretion of excess glucose and its associated calories in the urine.

5. No Direct Hypoglycemia Risk (Low Blood Sugar): Metformin works without stimulating insulin release, meaning it does not typically cause hypoglycemia (dangerously low blood sugar) when used alone. While the risk increases when combined with insulin or secretagogues, the core mechanism of the combination itself is generally lower-risk for hypoglycemia compared to other classes of drugs.